Although Smad2 has been shown to have tumor suppressor potential, with its mutations impacting the apoptosis signaling and inducing tumorigenicity in a rat prostate cell line [89], analysis of this downstream TGF-β intermediary’s expression and potential mutations in human prostate cancer samples showed no abnormality [90]. The gene discussed is TGFB1; the disease is prostate cancer.